Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17839891 | 0.89 | NR1H4 (0.54) | NR1H4FABP1 | |
| SCHEMBL17839893 | 0.89 | NR1H4 (0.54) | NR1H4FABP1 | |
| SCHEMBL17856126 | 0.89 | NR1H4 (0.54) | NR1H4FABP1 | |
| SCHEMBL17859521 | 0.85 | NR1H4 (0.49) | NR1H4FABP1 | |
| SCHEMBL17839433 | 0.85 | NR1H4 (0.53) | NR1H4FABP1 | |
| SCHEMBL22790285 | 0.85 | NR1H4 (0.51) | NR1H4FABP1 | |
| SCHEMBL17848929 | 0.85 | NR1H4 (0.53) | NR1H4FABP1 | |
| SCHEMBL19309759 | 0.85 | NR1H4 (0.55) | NR1H4FABP1 | |
| SCHEMBL23730806 | 0.82 | NR1H4 (0.55) | NR1H4 | |
| SCHEMBL22660083 | 0.81 | NR1H4 (0.54) | NR1H4FABP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751874-B2 | Hydroxy containing FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885FABP1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.